Third-line Antiretroviral Therapy, Including Raltegravir (RAL), Darunavir (drv/r) And/or Etravirine (ETR), is Well Tolerated and Achieves Durable Virologic Suppression over 144 Weeks in Resource-Limited Settings: ACTG A5288 Strategy Trial.Anchalee Avihingsanon,Michael D. Hughes,Robert Salata,Catherine Godfrey,Caitlyn McCarthy,Peter Mugyenyi,Evelyn Hogg,Robert Gross,Sandra W. Cardoso,Aggrey Bukuru,Mumbi Makanga, Sharlaa Badal-aesen,Vidya Mave,Beatrice Wangari Ndege,Sandy Nerette Fontain,Wadzanai Samaneka,Rode Secours,Marije Van Schalkwyk,Rosie Mngqibisa,Lerato Mohapi,Javier Valencia,Patcharaphan Sugandhavesa,Esmelda Montalban, Cornelius Munyanga,Maganizo Chagomerana,Breno R. Santos,Nagalingeswaran Kumarasamy,Cecilia Kanyama,Robert T. Schooley,John W. Mellors,Carole L. Wallis,Ann C. Collier,Beatriz GrinsztejnJournal of the International AIDS Society（2022）引用 1|浏览59暂无评分关键词A5288,darunavir,drug resistance,LMIC,third-line ART,144 weeks efficacyAI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
